Genitourinary Cancer
Conference Coverage
Diet, lifestyle factors add up in reducing risk of prostate cancer death
Key clinical point: Diet and lifestyle factors after a diagnosis of early prostate cancer may cut risk of death from the disease. Major finding:...
News
Bipolar androgen therapy may be new option for hormone-sensitive prostate cancer
Key clinical point: Bipolar androgen therapy may be an effective, more tolerable alternative to intermittent ADT. Major finding: Overall, 59% of...
News
Statins don’t appear to compromise effectiveness of abiraterone
Key clinical point: Use of statins does not reduce the effectiveness of abiraterone in men with castration-resistant prostate cancer. Major...
Conference Coverage
ADT resistance signature predicts failure of hormone therapy for prostate cancer
Key clinical point: The ADT resistance signature may help identify men who are unlikely to benefit from adjuvant ADT. Major finding: Among men...
News
Enzalutamide cuts disease progression, death in CRPC
Key clinical point: Enzalutamide cut the rate of disease progression or death by 76% in castration-resistant prostate cancer, with or without...
Conference Coverage
Hypofractionated radiation emerges as new standard of care for prostate cancer
Key clinical point: Hypofractionated radiation therapy was not inferior to conventional radiation therapy in men with low-risk or predominantly...
Conference Coverage
Testicular cancer patients who fare well early on have smooth sailing thereafter
Key clinical point: The longer men lived without any recurrence, the greater their probability of remaining alive and disease free in the future....
News
Adjuvant chemotherapy boosts survival for patients with locally advanced bladder cancer
Key clinical point: Adjuvant chemotherapy improves survival in patients with locally advanced bladder cancer who did not receive the neoadjuvant...
Conference Coverage
Poorer survival of African Americans with kidney cancer may be due to genomic differences
Key clinical point: The poorer survival of African American patients vs.
Conference Coverage
Combination of celecoxib, zoledronic acid benefits some with hormone-sensitive prostate cancer
Key clinical point: Adding celecoxib and zoledronic acid to standard of care improves outcomes in men with metastatic hormone-naive prostate...
News
Atezolizumab generates excitement in advanced urothelial cancer
Key clinical point: Atezolizumab is active in advanced urothelial cancer, especially in patients whose immune cells have higher expression of PD-...